Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02880670 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects
A Phase 1 study of Arthritis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02880670 is a Phase 1 study of Arthritis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 9 participants, below the 4,510-participant average among 48 other Arthritis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02880670, a Phase 1 study of Arthritis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single-dose, study in healthy males. The primary objective is to assess the pharmacokinetics (PK), metabolism, and routes of elimination of a single oral dose of radiolabeled BMS-986142 in healthy male subjects.
Conditions Studied
Interventions
- DRUG BMS-986142
Study Locations (1)
Wisconsin
- Covance Clinical Research Unit - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-08 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02880670
The ClinicalTrials.gov registry entry for NCT02880670 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,510-participant average among 48 other Arthritis trials with a reported enrollment target (100% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis appearing as the primary indexed condition, and to 1 intervention - of which BMS-986142 is the first listed.
NCT02880670 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02880670 about?
NCT02880670 is a clinical study titled "Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects". This is an open-label, single-dose, study in healthy males. The primary objective is to assess the pharmacokinetics (PK), metabolism, and routes of elimination of a single oral dose of radiolabeled BMS-986142 in healthy male subjects.
What is the current status of trial NCT02880670?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-08. Estimated completion is 2016-09.
What conditions does trial NCT02880670 study?
This clinical trial studies the following conditions: Arthritis.
What interventions are being tested in trial NCT02880670?
The interventions under investigation include: BMS-986142 (DRUG).
Who is sponsoring clinical trial NCT02880670?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02880670 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of the Walk With Ease Program for Fall Prevention
RECRUITING · Phase 1
-
Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations
COMPLETED · Phase 1
-
Sustained Acoustic Medicine (SAM) Combined With a Diclofenac Ultrasound Coupling Patch for Knee Osteoarthritis
COMPLETED · Phase 1
-
Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis
COMPLETED · Phase 1
-
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
RECRUITING
-
Expanding Exercise Programming for Veterans Through Telehealth
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.